Immunome Inc. Executives Execute Planned Share Sales Amid Bull Market Surge

Insider Activity Highlights a Strategic Shift at Immunome Inc. On April 2 2026, Chief Scientific Officer Higgins Jack sold 9,438 shares of Immunome’s common stock under a Rule 10b5‑1 trading plan, adding to a series of prior sales in March. The sale was executed at the market close price of $21.84, matching the company’s closing price on April 1. While the transaction represents only about 0.37 % of the shares Jack owned post‑sale (22,000 shares), it underscores a broader pattern of disciplined, plan‑based selling that has been ongoing since late‑2025.

What the Trend Means for Investors Immunome’s stock has delivered an impressive 271 % year‑to‑date return, yet its price‑earnings ratio sits at –9.27, reflecting the company’s continued heavy investment in R&D and pipeline development. The insider sales, largely governed by pre‑approved trading plans, suggest that senior management is not reacting to short‑term price fluctuations but is instead managing personal liquidity in a structured way. For investors, this can be reassuring: it signals a lack of “flight” from insider sentiment that might otherwise hint at impending trouble. However, the cumulative volume of shares sold by Jack and other executives (notably CFO Rosett Max’s 6‑transaction spree on the same day) could add pressure to the supply side, especially if the market interprets these moves as an attempt to diversify personal holdings ahead of a potential liquidity event, such as a partnership or acquisition.

A Profile of Higgins Jack Through the Lens of His Transactions Jack’s insider history shows a blend of equity purchases and sales, with a notable focus on employee stock options. In September 2025 he exercised 22,000 options for $1.35 each, immediately selling them for cash. He has also made a series of modest purchases (1,000‑share increments) in December 2025, suggesting a long‑term stake. His most recent sale on March 30 2026 of 6,291 shares at $0.00 (price omitted in the filing) reduced his holdings to 31,438 shares, a step that precedes the April sale. The pattern of option exercises followed by rapid liquidations indicates a strategy to harvest gains while retaining a core position that aligns with his scientific leadership role. This disciplined approach is consistent with a seasoned insider who balances personal financial planning with commitment to the company’s long‑term vision.

Company‑Wide Insider Activity: A Broader Context Beyond Jack, CFO Rosett Max executed six transactions on April 2: two sizeable purchases (over 31,000 shares at $1.05 and $1.35) and two large sales (63,656 shares at $21.91 and 1,344 shares at $22.48). These moves demonstrate a dynamic insider market at Immunome, where senior executives are actively managing their positions. The overall insider activity, coupled with the company’s robust share price momentum, paints a picture of a firm that is both growing quickly and actively managing ownership structures.

Strategic Takeaway for Investors The combination of structured insider selling, continued purchases, and a bullish share price trajectory suggests that Immunome’s leadership is confident in the company’s strategic direction while maintaining personal liquidity. For long‑term investors, the current insider activity does not appear to signal a looming downturn; rather, it reflects a mature approach to capital allocation. Watch for future quarterly earnings and pipeline milestones—particularly any announced collaborations or licensing deals—to gauge whether the company will maintain its aggressive growth trajectory and how insider activity may evolve in response to those events.